FDA Advisory Committee Briefing Document
Joint meeting of the
Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee
September 12, 2007
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
FDA Briefing Material (pdf)
Bayer HealthCare Pharmaceuticals
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Trasylol® (Aprotinin Injection), Bayer HealthCare Pharmaceuticals
Briefing Material (pdf)